The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides containing helper epitopes for malignant tumor.
Phase 1
- Conditions
- Malignant tumor
- Registration Number
- JPRN-UMIN000014435
- Lead Sponsor
- Medical Corporation Isokai Seren Clinic Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
The patients have been (1) Diagnosed or suspected of myelodysplastic syndrome (MDS). (2) Suspected of other severe clinical conditions or abnormal laboratory values. (3) Diagnosed or suspected of a mental disorder or mental symptoms. (4) Suspected of immunodeficiency and/or infection. Other exclusion criteria are as follows: (5) Pregnant, lactating or suspected of pregnancy. (6) Female patient rejecting to give consent to contraception during the therapy and for 70 days after the completion of the final administration. (7) Taking in adrenocortical steroid (at the equivalent of 10mg predonine or prednisolone per day). (8) Unsuitable for the therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method